EPSILOGEN
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
EPSILOGEN
Social Links:
Industry:
Biopharma Biotechnology Genetics Life Science Therapeutics
Founded:
2016-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.epsilogen.com
Total Employee:
11+
Status:
Active
Contact:
+44 (0) 203 657 7612
Email Addresses:
[email protected]
Total Funding:
39.95 M GBP
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS MailChannels UKFast.Net
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Arbor Biotechnologies
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Erasca
Erasca is a developer of oncology drugs intended to provide precision oncology options.
Genomics
Genomics plc aiming to lead the genomic transformation of healthcare.
PhagoMed
PhagoMed is a developer of a biotech platform designed to develop drugs and therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Epidarex Capital
Epidarex Capital investment in Series B - Epsilogen
ALSA Ventures
ALSA Ventures investment in Series B - Epsilogen
British Patient Capital
British Patient Capital investment in Series B - Epsilogen
Schroders Capital
Schroders Capital investment in Series B - Epsilogen
Novartis Venture Fund
Novartis Venture Fund investment in Series B - Epsilogen
Caribou Property
Caribou Property investment in Series B - Epsilogen
3B Future Health Fund
3B Future Health Fund investment in Series B - Epsilogen
Innovate UK
Innovate UK investment in Grant - Epsilogen
AlbionVC
AlbionVC investment in Series A - Epsilogen
Epidarex Capital
Epidarex Capital investment in Series A - Epsilogen
Official Site Inspections
http://www.epsilogen.com Semrush global rank: 5.16 M Semrush visits lastest month: 1.57 K
- Host name: 1109826.cloudwaysapps.com
- IP address: 104.248.174.226
- Location: London United Kingdom
- Latitude: 51.5353
- Longitude: -0.6658
- Timezone: Europe/London
- Postal: SL1
More informations about "Epsilogen"
About Us - Epsilogen
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. Evolved to treat parasitic infection, IgE has several key features that make it ideal for …See details»
Epsilogen - Crunchbase Company Profile & Funding
Organization. Epsilogen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Epsilogen is a developer of an immuno-oncology …See details»
Management Team - Epsilogen
Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and …See details»
Epsilogen - The Org
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours …See details»
Epsilogen Company Profile 2024: Valuation, Funding & Investors
Epsilogen General Information Description. Operator of an immuno-oncology company intended to develop immunoglobulin antibodies for the treatment of cancer. The company's offerings …See details»
Epsilogen Company Profile - Office Locations, Competitors ... - Craft
Epsilogen (formerly IGEM Therapeutics) is an immuno-oncology company specializing in the development of IgE antibody drugs to fight cancer. It is focused on the engineering structural …See details»
Epsilogen Ltd - LinkedIn
Epsilogen Ltd | 2,330 followers on LinkedIn. Harnessing the power of IgE | Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several …See details»
Epsilogen - Overview, News & Similar companies | ZoomInfo.com
Mar 5, 2024 Who is Epsilogen. Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE has several key features that make it …See details»
Epsilogen announces significant expansion of management team …
Apr 26, 2023 Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against …See details»
Board of Directors - Epsilogen
Marianne Uteng PhD is a Managing Director at NVF in Basel, Switzerland. Prior to that, she worked in Novartis Global Drug Development, and in the Pre-Clinical Safety Department …See details»
Epsilogen and Lonza Announce Successful Large-Scale GMP …
Mar 5, 2024 Epsilogen Contact Details Simon Conway Senior Managing Director FTI Consulting [email protected] +44 (0)20 3727 1000 Lonza Contact Details [email protected] …See details»
Epsilogen Completes £12.5 Million Series B Financing Expansion
Sep 9, 2024 LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the completion of a £12.5 …See details»
Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into …
Mar 2, 2022 Novartis has thrown its weight behind a “Cinderella antibody,” leading a 30.8 million pound sterling ($40.9 million) series B round that positions Epsilogen to try to create “a brand …See details»
Epsilogen appoints Ashley Nagle as Chief Business Officer and …
May 1, 2024 Epsilogen has made substantial progress over the last 12 months on all fronts and Ashley will spearhead our partnering discussions going forward. I would like to thank Dave for …See details»
Epsilogen Announces Initiation of Phase Ib Trial of MOv18 IgE
1 day ago Dr Tim Wilson, CEO of Epsilogen, said: “We are pleased to have initiated the Phase Ib study of MOv18 IgE, following the encouraging Phase I data. This is a key step in our goal …See details»
Scientific Founder - Epsilogen
The Scientific Founders at Epsilogen are the driving force behind the company’s groundbreaking research and scientific innovation in the field of immunoglobulin E (IgE) antibody-based cancer …See details»
Epsilogen Announces Completion of Oversubscribed £30.75 …
Mar 2, 2022 LONDON--(BUSINESS WIRE)--Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced it has secured £30.75 …See details»
Advisers - Epsilogen
Sophia is a Reader in translational cancer immunology at KCL and a globally-recognised expert on the use of IgE antibodies to fight cancer. She co-founded and Chairs the Task Force on …See details»
Epsilogen Announces Successful Completion of First Ever Clinical …
Jul 25, 2023 LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, notes the publication today of the final …See details»